Your Web Site
News source: Business Wire Pro-Pharmaceuticals, Inc. , a Company developing carbohydrate-based targeted therapeutic compounds to treat cancer and fibrosis, has completed an important step toward submission of a New Drug Application (NDA) for DAVANAT(R) by filing the Drug Master File (DMF) to the... [read full story]
